Deep vein thrombosis diagnosis

Indications for treatment with streptokinase include acute occlusion of arteries, deep vein thrombosis, and pulmonary embolism. Streptokinase therapy in coronary thrombosis, which is the usual cause of myocardial infarction (54,71,72), has proved to be valuable. In this frequently fatal condition, the enzyme is adrninistered intravenously at a dose of 1.5 million units over 60 min, or given by intracoronary infusion at a 20,000- to 50,000-unit bolus dose followed by 2000 to 4000 units/min for 60 min therapy must be instituted as soon as practicable after the diagnosis of heart attack is made. For deep vein thrombosis, pulmonary embolism, or arterial occlusion, streptokinase is infused at a loading dose of 250,000 units given over 30 min, followed by a maintenance dose of 100,000 units over a 60-min period. 

Clinical Presentation and Diagnosis of Deep Vein Thrombosis ... 

Haines ST, Bussey HI. Diagnosis of deep vein thrombosis. Am J Health Syst Pharm 1997 54 66-74. 

Thrombosis/embolism, diagnosis and treatment of disseminated intravascular coagulation (DIG), prophylaxis of deep vein thrombosis (DVT), clotting prevention Gearing intermittent infusion lines (heparin lock) to prevent clot formation at site... 

Baccarelli et al. (2008) studied in a case-control study 870 patients with deep vein thrombosis (DVT) and 1210 healthy controls from the Lombardy region in Italy, who were examined between 1995 and 2005. They estimated exposure to PMio in the year before DVT diagnosis (cases) or examination (controls) through area-specific mean levels obtained from ambient monitors. Each increase of 10 pg/ m in PMio was associated with a 70% increase in DVT risk (OR 1.70 95% Cl 1.30-2.23). 

Obstetric discharge, principal diagnosis of deep vein thrombosis, and obstetric patients are not included in this safety indicator. 

Douketis JD, Ginsberg JS, Haley S, Julian J, Dwyer M, Levine M, etal. Accuracy and safety of Tc-labeledanti-D-dimer (D1-80B3) Fab fragments (ThromboView(R)) in the diagnosis of deep vein thrombosis a phase II study. Thromb Res September 2012 130(3) 381-9. 

---